Literature DB >> 29632023

Eltrombopag mobilizes iron in patients with aplastic anemia.

Zhen Zhao1,2, Qian Sun1, Lori J Sokoll3, Michael Streiff4, Zhe Cheng5, Sophie Grasmeder6, Danielle M Townsley6, Neal S Young6, Cynthia E Dunbar6, Thomas Winkler6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29632023      PMCID： PMC5969382          DOI： 10.1182/blood-2018-01-826784

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Eltrombopag interference in routine chemistry testing.

Authors:  Verena Gounden; Zhen Zhao
Journal:  Ann Clin Biochem       Date:  2015-10-21       Impact factor: 2.057

2.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

Authors:  Ronan Desmond; Danielle M Townsley; Bogdan Dumitriu; Matthew J Olnes; Phillip Scheinberg; Margaret Bevans; Ankur R Parikh; Kinneret Broder; Katherine R Calvo; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

3.  Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.

Authors:  Michele P Lambert; Char M Witmer; Janet L Kwiatkowski
Journal:  Am J Hematol       Date:  2017-03-20       Impact factor: 10.047

4.  Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.

Authors:  Danielle M Townsley; Phillip Scheinberg; Thomas Winkler; Ronan Desmond; Bogdan Dumitriu; Olga Rios; Barbara Weinstein; Janet Valdez; Jennifer Lotter; Xingmin Feng; Marie Desierto; Harshraj Leuva; Margaret Bevans; Colin Wu; Andre Larochelle; Katherine R Calvo; Cynthia E Dunbar; Neal S Young
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

5.  Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Authors:  Patricia Evans; Reem Kayyali; Robert C Hider; John Eccleston; John B Porter
Journal:  Transl Res       Date:  2010-05-27       Impact factor: 7.012

6.  Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Authors:  Michael Roth; Britta Will; Guillermo Simkin; Swathi Narayanagari; Laura Barreyro; Boris Bartholdy; Roni Tamari; Constantine S Mitsiades; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2012-05-24       Impact factor: 22.113

7.  Eltrombopag: Investigation of Previously Reported Serum Discoloration and Negative Interference on a Total Bilirubin Diazo Method.

Authors:  David F Adams; Teresa S Sellers
Journal:  Arch Pathol Lab Med       Date:  2016-05       Impact factor: 5.534

8.  Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.

Authors:  Yanli Deng; Armina Madatian; Mary Beth Wire; Carolyn Bowen; Jung Wook Park; Daphne Williams; Bin Peng; Ernest Schubert; Frances Gorycki; Mark Levy; Peter D Gorycki
Journal:  Drug Metab Dispos       Date:  2011-06-06       Impact factor: 3.922

9.  Eltrombopag and improved hematopoiesis in refractory aplastic anemia.

Authors:  Matthew J Olnes; Phillip Scheinberg; Katherine R Calvo; Ronan Desmond; Yong Tang; Bogdan Dumitriu; Ankur R Parikh; Susan Soto; Angelique Biancotto; Xingmin Feng; Jay Lozier; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

10.  Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.

Authors:  Evangelia Vlachodimitropoulou; Yu-Lin Chen; Maciej Garbowski; Pimpisid Koonyosying; Bethan Psaila; Martha Sola-Visner; Nichola Cooper; Robert Hider; John Porter
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113
View more
  14 in total

1.  Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.

Authors:  Luigi J Alvarado; Heather D Huntsman; Hai Cheng; Danielle M Townsley; Thomas Winkler; Xingmin Feng; Cynthia E Dunbar; Neal S Young; Andre Larochelle
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 2.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Blood Adv       Date:  2018-11-13

Review 4.  Eltrombopag: Role in Cytopenias Following Hematopoietic Stem Cell Transplantation.

Authors:  Ram Vasudevan Nampoothiri; Rajat Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-24       Impact factor: 0.900

5.  Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation.

Authors:  Yang Gao; Fei Gao; Jimin Shi; Huarui Fu; He Huang; Yanmin Zhao
Journal:  J Zhejiang Univ Sci B       Date:  2021-08-15       Impact factor: 3.066

6.  Exploring the Potential of Eltrombopag: Room for More?

Authors:  Francesco Tarantini; Cosimo Cumbo; Luisa Anelli; Antonella Zagaria; Maria Rosa Conserva; Immacolata Redavid; Giorgina Specchia; Pellegrino Musto; Francesco Albano
Journal:  Front Pharmacol       Date:  2022-05-23       Impact factor: 5.988

7.  Studies of a mosaic patient with DBA and chimeric mice reveal erythroid cell-extrinsic contributions to erythropoiesis.

Authors:  Raymond T Doty; Xing Fan; David J Young; Jialiu Liang; Komudi Singh; Zahra Pakbaz; Ronan Desmond; Sara K Young-Baird; Settara C Chandrasekharappa; Frank X Donovan; Susan R Phelps; Thomas Winkler; Cynthia E Dunbar; Janis L Abkowitz
Journal:  Blood       Date:  2022-06-09       Impact factor: 25.476

8.  Long-term eltrombopag for bone marrow failure depletes iron.

Authors:  David J Young; Xing Fan; Emma M Groarke; Bhavisha Patel; Ronan Desmond; Thomas Winkler; Andre Larochelle; Katherine R Calvo; Neal S Young; Cynthia E Dunbar
Journal:  Am J Hematol       Date:  2022-03-26       Impact factor: 13.265

9.  Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.

Authors:  Xing Fan; Ronan Desmond; Thomas Winkler; David J Young; Bogdan Dumitriu; Danielle M Townsley; Fernanda Gutierrez-Rodrigues; Jennifer Lotter; Janet Valdez; Stephanie E Sellers; Ma Evette Barranta; Ruba N Shalhoub; Colin O Wu; Maher Albitar; Katherine R Calvo; Neal S Young; Cynthia E Dunbar
Journal:  Blood Adv       Date:  2020-04-28

10.  Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Authors:  Ayça Koca Yozgat; Göksel Leblebisatan; Sinan Akbayram; Simge Çınar Özel; Zeynep Karakaş; Erol Erduran; Şebnem Yılmaz; Ülker Koçak; Şule Ünal; Gül Nihal Özdemir; Meryem Albayrak; Emine Zengin; Yeşim Oymak; Özcan Bör; Hasan Fatih Çakmaklı; Murat Söker; Dilek Gürlek Gökçebay; Hüseyin Tokgöz; Barış Malbora; Serap Karaman; Tiraje Celkan; İlgen Şaşmaz; Neşe Yaralı; Hale Ören; Ayşegül Ünüvar; Namık Yaşar Özbek
Journal:  Turk J Haematol       Date:  2020-03-17       Impact factor: 1.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.